Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy

Stacey Schultz-Cherry, Maureen A. Mcgargill, Paul G. Thomas, Jeremie H. Estepp, Aditya H. Gaur, E. Kaitlynn Allen, Kim J. Allison, Li Tang, Richard J. Webby, Sean D. Cherry, Chun Yang Lin, Thomas Fabrizio, Elaine I. Tuomanen, Joshua Wolf, Ericka Kirkpatrick Roubidoux, Pamela Freiden, Tomi Mori, Diego R. Hijano, Hana Hakim, David C. BriceAshley Castellaw, Florian Krammer, David E. Wittman, Jason Hodges, Ronald H. Dallas, Valerie Cortez, Ana Vazquez-Pagan, Resha Bajracharya, Brandi L. Clark, Lee Ann Van De Velde, Walid Awad, Taylor L. Wilson, Allison M. Kirk, Randall T. Hayden, James Hoffman, Jamie Russell-Bell, James Sparks

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference"might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration.: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995;

Original languageEnglish
Article numberofab420
JournalOpen Forum Infectious Diseases
Issue number9
StatePublished - 1 Sep 2021


  • Antibody
  • COVID-19
  • SARS-CoV-2
  • bamlanivimab
  • vaccine failure


Dive into the research topics of 'Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy'. Together they form a unique fingerprint.

Cite this